Why Is Mersana (MRSN) Up 200% in Premarket? Day One Biopharma Agrees to $25/Share Buyout

Mersana Therapeutics (NASDAQ: MRSN) stock skyrocketed over 200% in premarket trading on November 13, 2025, following the announcement of a definitive merger agreement with Day One Biopharmaceuticals (NASDAQ: DAWN). The acquisition offer values Mersana at $25 per share upfront in cash, representing a massive premium over the previous day’s closing price of $8.87.

With the stock surging to $26.53 in premarket trading as of 8:00 AM EST, investors are reacting enthusiastically to the deal that could ultimately be worth up to $55.25 per share including potential milestone payments.

Buyout Includes $25 Cash Per Share Plus Up to $30.25 in Milestones

Day One Biopharmaceuticals will launch a tender offer to acquire all outstanding MRSN shares at $25 per share in cash at closing. Additionally, shareholders will receive one non-tradable contingent value right (CVR) per share, which could provide up to $30.25 per CVR in cash upon achievement of specific clinical, regulatory, and commercial milestones related to Mersana’s B7-H4-directed antibody-drug conjugate, Emi-Le. This brings the total potential consideration to $55.25 per share.

The transaction represents a total equity value of approximately $129 million at closing, with a total deal value of up to approximately $285 million when including the milestone payments. Day One expects to finance the acquisition entirely with existing cash resources. The tender offer is expected to commence within 10 business days of November 12, 2025, with the transaction anticipated to close by the end of January 2026, subject to customary closing conditions including the tender of a majority of Mersana’s shares and U.S. regulatory approvals.

Approximately 8.5% of Mersana’s outstanding shares, held by company executives, directors, and certain stockholders affiliated with Bain Capital Life Sciences, are already committed to the tender offer, providing a foundation of shareholder support for the deal. The acquisition will make Mersana a wholly-owned subsidiary of Day One once completed.

Join our Telegram group and never miss a breaking digital asset story.

MRSN Rebounds Strongly After Heavy Losses and Analyst Cuts

Mersana Therapeutics stock experienced a dramatic surge in premarket trading on November 13, 2025, jumping 199.13% to $26.53 as of 8:00 AM EST, compared to its previous closing price of $8.87. The premarket gain of $17.66 per share reflects investor enthusiasm for the $25 cash upfront offer, which represents a 182% premium over the November 12 closing price. The stock had been trading in a 52-week range of $5.21 to $70.72, with the acquisition price falling near the middle of that range.

Prior to the acquisition announcement, MRSN had been experiencing significant challenges, with year-to-date returns down 75.19% and one-year returns declining 83.87%. The company’s market capitalization had shrunk to just $44.27 million as of November 11, 2025, reflecting investor concerns about the clinical-stage biotech’s cash burn and pathway to commercialization. The stock’s average trading volume of 61,390 shares paled in comparison to the 21,677 shares traded on November 12, indicating relatively light interest before the deal was announced.

Analyst sentiment prior to the acquisition had been cautiously optimistic, with a consensus price target of $28.29 and most analysts maintaining “Buy” ratings on the stock. The most recent analyst action came from Truist Securities on August 14, 2025, which maintained a “Buy” rating but dramatically reduced its price target from $250 to $36, reflecting concerns about the company’s valuation and clinical progress. The acquisition offer at $25 per share, with potential milestone payments bringing total value to $55.25, effectively validates the bulls’ thesis while providing immediate liquidity to shareholders.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.